Following the success of anti-CTLA-4 therapy, antibodies targeting programmed cell death protein 1 (PD-1), or its ligand PD-L1, proved to be effective at improving overall survival in a wide variety of cancers (2–7). Here, CTLA4 is linked to cancer.